AKT1 - A New Marker for Tamoxifen Resistance in ER-Dependent Breast Cancer

doi 10.21236/ada432994
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Defense Technical Information Center

Related search

Estrogen Receptor (ER ) Level but Not Its ER Cx Variant Helps to Predict Tamoxifen Resistance in Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2004English

ERK/MAPK Regulates ERRγ Expression, Transcriptional Activity and Receptor-Mediated Tamoxifen Resistance in ER+ Breast Cancer

FEBS Journal
BiochemistryCell BiologyMolecular Biology
2014English

Tetraploidy: A New Marker for Breast Cancer?

Journal of Carcinogenesis & Mutagenesis
2013English

miR-375 Inhibits Cancer Stem Cell Phenotype and Tamoxifen Resistance by Degrading HOXB3 in Human ER-positive Breast Cancer

Oncology Reports
MedicineCancer ResearchOncology
2017English

A Molecular Model for the Mechanism of Acquired Tamoxifen Resistance in Breast Cancer

European Journal of Cancer
Cancer ResearchOncology
2014English

Moesin Is an Independent Prognostic Marker for ER‑positive Breast Cancer

Oncology Letters
Cancer ResearchOncology
2018English

ERR Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2015English

Role of Dynein Light Chain 1 in Tamoxifen Resistance in Breast Cancer

2007English

AKT1 Inhibits Epithelial-To-Mesenchymal Transition in Breast Cancer Through Phosphorylation-Dependent Twist1 Degradation

Cancer Research
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy